001     157657
005     20240229123143.0
024 7 _ |a 10.3390/nu12082488
|2 doi
024 7 _ |a pmid:32824839
|2 pmid
024 7 _ |a altmetric:88463234
|2 altmetric
037 _ _ |a DKFZ-2020-01745
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Brenner, Hermann
|0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
|b 0
|e First author
245 _ _ |a Vitamin D Insufficiency and Deficiency and Mortality from Respiratory Diseases in a Cohort of Older Adults: Potential for Limiting the Death Toll during and beyond the COVID-19 Pandemic?
260 _ _ |a Basel
|c 2020
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1608046435_15088
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C070#LA:C070#
520 _ _ |a The COVID-19 pandemic goes along with increased mortality from acute respiratory disease. It has been suggested that vitamin D3 supplementation might help to reduce respiratory disease mortality. We assessed the prevalence of vitamin D insufficiency and deficiency, defined by 25-hydroxyvitamin D (25(OH)D) blood levels of 30-50 and <30 nmol/L, respectively, and their association with mortality from respiratory diseases during 15 years of follow-up in a cohort of 9548 adults aged 50-75 years from Saarland, Germany. Vitamin D insufficiency and deficiency were common (44% and 15%, respectively). Compared to those with sufficient vitamin D status, participants with vitamin D insufficiency and deficiency had strongly increased respiratory mortality, with adjusted hazard ratios (95% confidence intervals) of 2.1 (1.3-3.2) and 3.0 (1.8-5.2) overall, 4.3 (1.3-14.4) and 8.5 (2.4-30.1) among women, and 1.9 (1.1-3.2) and 2.3 (1.1-4.4) among men. Overall, 41% (95% confidence interval: 20-58%) of respiratory disease mortality was statistically attributable to vitamin D insufficiency or deficiency. Vitamin D insufficiency and deficiency are common and account for a large proportion of respiratory disease mortality in older adults, supporting the hypothesis that vitamin D3 supplementation could be helpful to limit the burden of the COVID-19 pandemic, particularly among women.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Holleczek, Bernd
|0 P:(DE-He78)53e1a2846c69064e27790dbf349ccaec
|b 1
700 1 _ |a Schöttker, Ben
|0 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
|b 2
|e Last author
773 _ _ |a 10.3390/nu12082488
|g Vol. 12, no. 8, p. 2488 -
|0 PERI:(DE-600)2518386-2
|n 8
|p 2488
|t Nutrients
|v 12
|y 2020
|x 2072-6643
909 C O |p VDB
|o oai:inrepo02.dkfz.de:157657
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)53e1a2846c69064e27790dbf349ccaec
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)c67a12496b8aac150c0eef888d808d46
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
914 1 _ |y 2020
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NUTRIENTS : 2018
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2020-01-10
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2020-01-10
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2020-01-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2020-01-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2020-01-10
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2020-01-10
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|f 2020-01-10
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-01-10
920 2 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 0 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)C070-20160331
|k C070
|l C070 Klinische Epidemiologie und Alternf.
|x 0
920 1 _ |0 I:(DE-He78)C120-20160331
|k C120
|l Präventive Onkologie
|x 1
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C070-20160331
980 _ _ |a I:(DE-He78)C120-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21